机构:[1]Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing 100000, China神经科系统神经内科首都医科大学宣武医院[2]Beijing Geriatric Medical Research Center and Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing 100000, China[3]Vascular Ultrasonography Department, Xuanwu Hospital, Capital Medical University, Beijing 100000, China医技科室血管超声科首都医科大学宣武医院
Several clinical parameters and biomarkers have been proposed as prognostic markers for stroke. However, it has not been clarified whether the risk factors affecting the prognosis of patients with recurrent and first-ever stroke are similar. In this study, we aimed to explore the relationship between soluble lectin-like oxidized low-density lipoprotein receptor 1 (sLOX-1) levels and the prediction of the functional outcome in patients with recurrent and first-ever stroke. A total of 266 patients with recurrent and first-ever stroke, who underwent follow-up for 3 months, were included in this study. Plasma samples were collected within 24 h after onset. The results showed that biomarkers for the prognosis of patients with recurrent stroke were different from that of those with first-ever stroke. sLOX-1 levels were correlated with modified Rankin Scale scores of patients with recurrent stroke alone (r = 0.3232, p = 0.001). sLOX-1 levels were also associated with an increased risk of unfavorable outcomes in patients with recurrent stroke with an adjusted odds ratio of 1.489 (95% confidence interval, 1.204-1.842, p < 0.0001). Combining the risk factors showed greater accuracy for prognosis, yielding a sensitivity of 93.2% and a specificity of 75%, with an area under the curve of 0.916, evaluated by the receiver operating characteristic curve. These findings suggest that the diagnosis and prognosis are different between patients with recurrent stroke and those with first-ever stroke, and sLOX-1 level is an independent prognostic marker in patients with recurrent stroke.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [82001390, 81971222, 81801299]; Capital Funds for Health Improvement and Research [2020-2-1032]
第一作者机构:[1]Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing 100000, China[2]Beijing Geriatric Medical Research Center and Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing 100000, China
通讯作者:
通讯机构:[1]Institute of Cerebrovascular Disease Research and Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing 100000, China[2]Beijing Geriatric Medical Research Center and Beijing Key Laboratory of Translational Medicine for Cerebrovascular Diseases, Beijing 100000, China
推荐引用方式(GB/T 7714):
Zheng Yangmin,Huang Yuyou,Li Lingzhi,et al.sLOX-1: A Molecule for Evaluating the Prognosis of Recurrent Ischemic Stroke[J].NEURAL PLASTICITY.2021,2021:doi:10.1155/2021/6718184.
APA:
Zheng, Yangmin,Huang, Yuyou,Li, Lingzhi,Wang, Pingping,Wang, Rongliang...&Luo, Yumin.(2021).sLOX-1: A Molecule for Evaluating the Prognosis of Recurrent Ischemic Stroke.NEURAL PLASTICITY,2021,
MLA:
Zheng, Yangmin,et al."sLOX-1: A Molecule for Evaluating the Prognosis of Recurrent Ischemic Stroke".NEURAL PLASTICITY 2021.(2021)